Lyudmila Bazhenova, MD of UC San Diego Health explains how to choose one ALK inhibitor over the others at the…
Browsing: Acute Lymphoblastic Leukemia
Lyudmila Bazhenova, MD of UC San Diego Health discusses the reliability of the ALK biomarker and whether or not physicians…
Aref Al-Kali, MD of Mayo Clinic discusses some of the challenges in treating elderly acute myeloid leukemia patients at the…
Aref Al-Kali, MD of Mayo Clinic discusses the use of the Leukostat test in clinical practice, which was approved with…
Aref Al-Kali, MD of Mayo Clinic discusses the approval of midostaurin for FLT3+ AML patients. This was recorded at the…
Aref Al-Kali, MD of Mayo Clinic discusses the important data presented on FLT3 mutant AML at the 2017 Annual Meeting…
An educational overview of facts in Childhood Cancer | Pediatric Oncology (an educational tool designed to be shared by healthcare…
Overview of facts in breast cancer (an educational tool designed to be shared by healthcare professionals with patients and caregivers)
H. Jack West, MD of Swedish Cancer Institute gives an overview of the use of gefinitib compared to standard chemotherapy…
H. Jack West, MD of Swedish Cancer Institute discusses the updated results of the KEYNOTE-021 study for patients with advanced…
H. Jack West, MD of Swedish Cancer Institute discusses an abstract that focused on the efficacy and safety of a…
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ARCHER 1050 trial for non-small cell lung…
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ALEX trial for ALK+ non-small cell lung…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take home of the POLLUX and CASTOR…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology argues that the take-home message for the follow-up on…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take-home message of the LATITUDE study at…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the LATITUDE trial, a phase III trial on…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview a four year follow-up study on…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology summarizes common questions that are asked regarding the updates…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains a common question that’s usually asked regarding the…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains which combination improved survival for patients with prostate…
Katja Weisel, MD of Janssen Oncology gives an overview of her abstract, which focuses on two randomized phase III trials…
Katja Weisel, MD of Janssen Oncology explains further the next steps for the POLLUX and CASTOR trials which include extending…
Katja Weisel, MD of Janssen Oncology discusses the impact of the POLLUX and CASTOR trial on clinical practice, which are…
Katja Weisel, MD of Janssen Oncology summarizes a poster presentation that focused on the anti-CD38 antibody in refractory myeloma patients…
Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the next steps for the clinical trial at the 2017…
Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the impact of atezolizumab on clinical practice and future clinical…
Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of the practice-changing data on lung cancer at…
Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of her presentation, which focuses on the use…
Jalaja Potluri, MD of AbbVie Inc. discusses what’s next for her study and her hopes for the drug to become…
Jalaja Potluri, MD of AbbVie Inc. discusses common questions colleagues ask regarding her study at the 2017 ASCO Annual Meeting…
Jalaja Potluri, MD of AbbVie Inc. gives an overview of her abstract, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of…
Jalaja Potluri, MD of AbbVie Inc. discusses the treatment trends for 2017 in acute myeloid leukemia at the 2017 ASCO…
Nathan Pennell, MD, PhD of Cleveland Clinic discusses what’s next for his study on maintenance pembrolizumab for patients with small…
Nathan Pennell, MD, PhD of Cleveland Clinic gives an overview of his abstract, which focused on the use of maintenance…
Nathan Pennell, MD, PhD of Cleveland Clinic discusses common questions that colleagues ask him regarding pembrolizumab, which is if there…
Nathan Pennell, MD, PhD of Cleveland Clinic summarizes promising presentations on targeted treatments in patients with non-small cell lung cancer…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. gives an overview of Advaxis’ Lm Technology, which alters Listeria monocytogenes…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains what axalimogene filolisbac is and the use of it in…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the pipeline of Lm Technology at the 2017 ASCO Annual…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains how Lm Technology works in the system and what are…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the practice-changing studies on immuno-oncology coming out of ASCO 2017.…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. discusses the NEO program which is a collaboration between Amgen and…
Andrew Norden, MD of IBM Watson Health discusses the future of Watson for Oncology in clinical practice at the 2017…
Andrew Norden, MD of IBM Watson Health summarizes the use of Watson technology in the field of oncology at the…
Andrew Norden, MD of IBM Watson Health discusses questions and concerns colleagues have regarding Watson for Oncology, which include whether…
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute discusses the next steps for his study, which include combining c-met targeted therapies…
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute gives an overview of his presentation, Differential expression of c-Met between primary and…
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute summarizes the common questions colleagues ask him concerning his study on c-Met expression…